CADILA HEALTHCARE LTD. - 532321 - Record Date For Interim Dividend 2019-2020
Record Date for Interim Dividend 2019-202011-03-2020
11-03-2020
CADILA HEALTHCARE LTD. - 532321 - Board Meeting Intimation for Interim Dividend 2019-2020
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2020 ,inter alia, to consider and approve Interim Dividend 2019-202011-03-2020
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Restructuring
Transfer of Animal Healthcare Business of the Company to its wholly owned subsidiary, Zydus Animal Health and Investments Limited, on a going concern basis.11-03-2020
Cadila Healthcare to focus on innovation and IP creation: Sharvil Patel
"Our next strategy is that we want to be IP (intellectual property) driven company and our strong belief has always been that we have to make efforts in research because that's the true disrupter for us," Sharvil Patel said.09-03-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and XOMA announce IL-2-Based-Immuno-Oncology Therapy Licensing Agreement09-03-2020
CADILA HEALTHCARE LTD. - 532321 - Notification
The USFDA inspected the Company's formulations manufacturing facility located at Baddi from 2nd to 9th March, 2020. This was a cGMP and Post Approval Inspection. At the end of the inspection, no observation (483) is issued.09-03-2020
What to watch: Nod for liver drug may boost Cadila Healthcare
Cadila Healthcare on Thursday announced that the Drug Controller General of India has approved its New Drug Application for Saioglitazar for the treat06-03-2020
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus announces world's first drug for the treatment of Non-Cirrhotic NASH05-03-2020
Cadila Healthcare Ltd - 532321 - Notification
We hereby inform that the Company has received the approval from the Drug Controller General of India (DCGI) for its New Drug Application (NDA) for Saroglitazar for the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India.05-03-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a copy of press release dated March 4, 2020 titled 'Zydus receives final approval from the USFDA for Emtricitabine and Tenofovir disoproxil Fumarate Tablets 200 mg / 300 mg'.04-03-2020